학술논문
Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial
Document Type
article
Author
Christina M. Eckhardt; Matthew J. Cummings; Kartik N. Rajagopalan; Sarah Borden; Zachary C. Bitan; Allison Wolf; Alex Kantor; Thomas Briese; Benjamin J. Meyer; Samuel D. Jacobson; Dawn Scotto; Nischay Mishra; Neena M. Philip; Brie A. Stotler; Joseph Schwartz; Beth Shaz; Steven L. Spitalnik; Andrew Eisenberg; Eldad A. Hod; Jessica Justman; Ken Cheung; W. Ian Lipkin; Max R. O’Donnell
Source
Trials, Vol 21, Iss 1, Pp 1-3 (2020)
Subject
Language
English
ISSN
1745-6215
Abstract
Abstract Objectives The aim of this study is to evaluate the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in hospitalized adults with severe SARS-CoV-2 infection. Trial Design This is a prospective, single-center, phase 2, randomized, controlled trial that is blinded to participants and clinical outcome assessor. Participants Eligible participants include adults (≥ 18 years) with evidence of SARS-CoV-2 infection by PCR test of nasopharyngeal or oropharyngeal swab within 14 days of randomization, evidence of infiltrates on chest radiography, peripheral capillary oxygen saturation (SpO2) ≤ 94% on room air, and/or need for supplemental oxygen, non-invasive mechanical ventilation, or invasive mechanical ventilation, who are willing and able to provide written informed consent prior to performing study procedures or who have a legally authorized representative available to do so. Exclusion criteria include participation in another clinical trial of anti-viral agent(s)* for coronavirus disease-2019 (COVID-19), receipt of any anti-viral agent(s)* with possible activity against SARS-CoV-2